WO1986002100A1 - Vecteurs contenant un gene pour une proteine presentant une activite d'activation d'erythroides et procede par adn recombinant de production de cette proteine - Google Patents

Vecteurs contenant un gene pour une proteine presentant une activite d'activation d'erythroides et procede par adn recombinant de production de cette proteine Download PDF

Info

Publication number
WO1986002100A1
WO1986002100A1 PCT/US1985/001900 US8501900W WO8602100A1 WO 1986002100 A1 WO1986002100 A1 WO 1986002100A1 US 8501900 W US8501900 W US 8501900W WO 8602100 A1 WO8602100 A1 WO 8602100A1
Authority
WO
WIPO (PCT)
Prior art keywords
epa
protein
gene
cells
cell
Prior art date
Application number
PCT/US1985/001900
Other languages
English (en)
Inventor
Eugene Brown
Steven C. Clark
David W. Golde
Judith C. Casson
Rodney Hewick
Carol A. Westbrook
Original Assignee
Sandoz Ltd.
The Regents Of The University Of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sandoz Ltd., The Regents Of The University Of California filed Critical Sandoz Ltd.
Publication of WO1986002100A1 publication Critical patent/WO1986002100A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • This invention relates to the production of a protein having erythroid-potentiating activity (EPA) and particularly to a pure EPA protein, to vectors containing the gene for expressing said protein, to microorganisms and mammalian cells transformed with said vectors, and to methods for producing said protein by recombinant DNA techniques.
  • EPA erythroid-potentiating activity
  • progenitor cells for Tlymphocytes, B lymphocytes, granulocytes, macrophages, red blood cells, platelets, and eosinophils, as well as earlier progenitors which can individually give rise to several of the mature cell types, have been studied experimentally both in vivo and in vitro (Dexter, T.M. 1983 J. Pathology 141 415-433). It has been determined in vitro that proliferation and/or differentiation of each progenitor cell type depends upon "factors" which have been derived from various sources. For example, T lymphocytes require T lymphocytes.
  • T-cell growth factor (IL-2) and some of the later progenitors of red blood cells require a factor called erythropoietin.
  • erythrocyte progenitors have been distinguished by the time course of colony formation in vitro and the characteristics of the colonies produced. Although there is a continuum with respect to the maturity of erythroid colony-forming cells, the most mature of these is generally referred to as colony-forming unit - erythroid (CFU-E), giving rise to relatively small colonies consisting of 8 to 64 hemoglobinized cells.
  • CFU-E colony-forming unit - erythroid
  • the burst-forming unit (BFU-E) is a more primitive erythroid progenitor.
  • the BFU-Es require more time to mature than CFU-Es and they can give rise to very large colonies containing up to thousands of cells with multiple subcolonies.
  • the CFU-E is thought to arise from the BFU-E.
  • the CFU-E is sensitive to erythropoietin (EPO) whereas the BFU-E is relatively insensitive to EPO.
  • BPA burst-promoting activity
  • EPA erythroid-potentiating activity
  • EPA peripheral blood mononuclear cells
  • bone-marrow conditioned medium urine from anemic patients, serum, and normal and neoplastic cells of T-lymphocyte and mononuclear phagocyte lineage.
  • the most widely used source of EPA is lectin-stimulated lymphocytes.
  • Medium conditioned by phytohemagglutinin (PHA-), concanavalin-A- and pokeweed mitogen-stimulated lyrophoid populations consistently produces EPA. Erythroid-potentiating activity is also released by lymphoid cells responding to antigen. It is most likely that in these circumstances the EPA is being elaborated by activated T lymphocytes. Consistent with this in vitro evidence for production of EPA by T lymphocytes are studies in which erythroid colony formation in vivo is greatly stimulated by addition of T lymphocytes.
  • EPA appears to be an acidic glycoprotein of molecular weight about 45,000, although it exhibits a degree of size and charge heterogeneity.
  • G,M-CSF granulocyte-macrophage colony-stimulating factor
  • the "purified" EPA retained an activity that stimulates the formation of mixed myeloid colonies in vitro, and may be employed to stimulate the formation and growth of myeloic cells including granulocytes, macrophages, megacaryocytes and mast cells.
  • EPA Because of its stimulating activity on erythroid progenitors, EPA can be useful for the treatment of anemia associated with chronic renal failure and for adjunctive therapy in patients receiving cancer or other chemotherapy. An adequate source of EPA will also be of great value in medical research to study the growth and formation of erythroid cells. EPA treatment can also be used for chronic diseases having associated anemia such as rheumatoid arthritis, tuberculosis, osteomyelitis, chronic urinary tract infections, and some malignancies. As in the anemia or chronic renal failure, EPA will be useful in treating the low red blood cell counts of patients with the above chronic diseases, however it will not treat the underlying basic disease process.
  • transfusion related infections which include hepatitis A, hepatitis B, non A and non B hepatitis, infectious mononucleosis, CMV disease, toxoplasmosis, malaria, syphillis and trypanosomiasis will be reduced.
  • One method of gene isolation is based upon knowing part or all of the amino acid sequence of the protein encoded by the gene.
  • Each of the twenty commonly occurring amino acids is encoded by one or more triplets of nucleotides called codons (for discussion see J.D. Watson, Molecular Biology of the Gene. (W.A. Benjamin, Inc., 1977, p. 347-377). Knowing the deoxyribonucleotide sequence of the gene (or DNA sequence which codes for a particular protein) allows the exact description of that protein's amino acid sequence. However, the converse is not true; for example, although tryptophan or methionine are coded for by only one codon, the other amino acids can be coded for by up to six codons.
  • a pool of synthetic oligonucleotides corresponding to all possible combinations of codons for a particular sequence of amino acids within a protein, should include the nucleotide sequence which in fact occurs in the gene encoding that protein.
  • Such synthetic oligonucleotide pools can be used to screen cloned gene libraries by standard techniques in order to identify the clone of interest.
  • the present invention overcomes these problems and provides a ready souce of EPA using recombinant DNA technology.
  • the present invention provides a substantially pure EPA protein having a biological activity of at least about 10 6 units per mg of protein and having an apparent molecular weight of about 28,000 daltons as determined by SDS-PAGE analysis on 10 percent polyacrylamide gel, a cloned EPA gene coding for such EPA protein, a recombinant vector containing the EPA gene, a microorganism or mammalian cell transformed with such a recombinant vector, and a method for producing EPA by expressing said EPA gene by culturing said microorganism or mammalian cell.
  • Purified EPA stimulates the growth of both early and late erythroid precursors from human bone marrow, as well as colony formation by the K562 erythroleukemia cell line.
  • Fig. 1 is a schematic illustrating the. preparation of plasmid pTPL from plasmid pAdD26SVpA (3) .
  • Fig. 2 is a schematic continuing f rom Fig. 1 and illustrating the preparation of plasmid p91023 from plasmid pTPL.
  • Fig. 3 is a schematic continuing from Fig. 2 and illustrating plasmid p91023(B).
  • Fig. 4 sets forth a nucleotide sequence containing an EPA gene cloned in accord with one embodiment of this invention along with the deduced amino acid sequence of the EPA protein that the gene encodes.
  • Fig. 5 sets forth another nucleotide sequence containing a sequence coding for EPA in accord with another embodiment of the invention along with the deduced amino acid sequence of the EPA protein encoded thereby.
  • Amplification means the process by which cells produce gene repeats within their chromosomal DNA.
  • Downstream means the direction going towards the 3' end of a nucleotide sequence.
  • An enhancer is a nucleotide sequence that can potentiate the transcription of genes independent of the identity of the gene, the position of the sequence in relation to the gene, or the orientation of the sequence.
  • a gene is a deoxyribonucleotide sequence coding for a given mature protein.
  • a gene shall not include untranslated flanking regions such as RNA transcription initiation signals, polyadenylation addition sites, promoters or enhancers.
  • a selection gene is a gene that confers a phenotype on cells which express the gene as a detectable protein.
  • a selection agent is a condition or substance that enables one to detect the expression of a selection gene.
  • Phenotype means the observable properties of a cell as expressed by the cellular genotype.
  • Genotype means the genetic information contained within a cell as opposed to its expression, which is observed as the phenotype.
  • Ligation is the process of forming a phosphodiester bond between the 5' and 3' ends of two DNA strands. This may be accomplished by several well known enzymatic techniques, including blunt end ligation by T4 ligase.
  • Orientation refers to the order of nucleotides in a DNA sequence.
  • An inverted orientation of a DNA sequence is one in which the 5' to 3' order of the sequence in relation to another sequence is reversed when compared to a point of reference in the DNA from which the sequence was obtained.
  • points of reference can include the direction of transcription of other specified DNA sequences in the source DNA or the origin of replication of replicable vectors containing the sequence.
  • Transcription means the synthesis of RNA from a DNA template.
  • Transformation means changing a cell's genotype by the stable transfection of cells with exogenous DNA. Transformation may be detected in some cases by an alteration in cell phenotype. Transformed cells are called transformants. Pre-transformation cells are referred to as parental cells.
  • Translation means the synthesis of a polypeptide from messenger RNA.
  • Erythroid-potentiating activity can be derived from a number of cellular sources including peripheral blood mononuclear cells, bone-marrow conditioned medium, urine from anemic patients, serum, and normal and neoplastic cells of T-lymphocyte and mononuclear phagocyte lineage. Because EPA has not been purified to homogeneity and because the assay for EPA is complex, the amino acid sequence for EPA is unknown. Thus, an oligonucleotide probe for EPA mRNA could not be predicted with any degree of certainty from any literature sources.
  • the partially purified EPA would not permit an analysis sufficient to construct possible oligonucleotide probes for EPA. Thus, further purification to substantial homogeneity was required. Such purification was accomplished in accord with the present invention by sequential concentration, ammonium sulfate precipitation, lentil-lectin affinity chromatography, gel filtration and reverse phase high performance liquid chromatography (HPLC). EPA was assayed by its ability to stimulate the growth of large erythroid colonies (bursts) from normal human peripheral blood. The purified EPA in accord with the present invention has an apparent molecular weight of 28,000 and appears as a single band when analyzed by SDS-PAGE under reducing or nonreducing conditions.
  • the EPA protein was analyzed on a gas phase sequenator to obtain a target sequence which was sufficient to predict possible DNA sequences and make oligonucleotide probes.
  • T-lymphocytes were induced with phytohemagglutinin (PHA) and phorbol myristic acid (PMA) to enhance their lymphokine production.
  • PHA phytohemagglutinin
  • PMA phorbol myristic acid
  • the cells were centrifuged and cytoplasmic RNA was prepared by a standard gentle lysis procedure. Polyadenylated messenger RNA was then prepared by chromatography on oligo dT cellulose.
  • First strand cDNA was prepared using standard methods using the mRNA prepared above. To enrich for sequences specific for lymphokines, the first strand cDNA was hybridized with an excess of mRNA from cells that do not make lymphokines. Most of the sequences expressed in the T-lymphocytes that produce lymphokines will also be expressed in, for instance, B-cell lines and immature T-cell lines. A small fraction of sequences will be found only in the starting T-lymphocyte cell line. Most of the single stranded cDNA will anneal to the mRNA from the B-cell lines or immature T-cell lines and become double stranded. The cDNA unique to the starting T-lymphocyte cell line remains single stranded. The single and double stranded DNA are separated by chromatography on hydroxylapatite, thereby substantially concentrating the lymphokine sequences.
  • the single stranded cDNA was then converted to double- stranded form by treatment with the Klenow fragment of DNA polymerase I using standard techniques.
  • the loopback form was cleaved with Sl-nuclease and C-tails were added using terminal transferase by standard methods.
  • the C-tailed cDNA was annealed with G-tailed pBR322 and used to transform E. coli.
  • E. coli clones were spread onto agar plates and the colonies were lifted off with nitrocellulose filter disks.
  • replicas were made by carefully placing a pre-wetted f ilter on top of the original filter.
  • the replica f ilters were aligned with the original by punching 3 asymmetrical holes through the f ilters with a needle.
  • the replica filters were removed to f resh plates and grown.
  • the plasmid DNA in each colony was amplified in situ by transferring the filters to fresh plates containing 100 ug/ml chloramphenicol and incubating overnight.
  • these replica filters were prepared for standard colony hybridization by treatment with base, followed by neutralization and drying.
  • the dried f ilters were baked to f ix the liberated DNA to the nitrocellulose.
  • DNA from each candidate clone was purified using cesium chloride equilibrium density centrifugation and sequenced using standard dideoxy. sequencing with pool 14-5. as the primer. The complete nucleotide sequence was obtained by subcloning the Pstl fragments of the clone (the EPA gene was found to have 3 internal
  • oligonucleotide primers were synthesized for use in sequencing the plasmid DNA directly (as described above with pool 14-5).
  • One of these primers d(T-G-C-A-C-C-T-G-T-G-T-C-C-C-A-C-C-) encoded the end of the mature protein and could be used for insertion into the bacterial expression vector as well as sequencing at the 5' end of the coding region.
  • a second primer; d(G-A-G-G-A-G-T-T-T-T-C-T-C-A-T-T-G-C-T-G) encoded the region near the 3' end of the first Pstl fragment and could be used to sequence through the three Pstl sites towards the 3' end of the clone.
  • the final primer; d (C-C-A-C-A-A-G-C-A-A-T-G-A-G-G-T-G-C-C-) was complementary to the mRNA strand near the 5' end of the 3' Pst fragment of the clone and could be used to sequence toward the 5' end of the clone through the 3 Pstl sites.
  • DNA sequence of the EPA gene of clone 57 is illustrated in Fig. 4 along with the amino acid sequence of the translated protein product.
  • EPA cDNA clone Once the full length EPA cDNA clone is obtained, known and appropriate means are utilized to express the EPA protein, e. g. insertion into an appropriate vector, transfection into an appropriate host, selection of transformants, and culturing these transformants to express EPA activity.
  • Host-vector systems for the expression of EPA may be procaryotic, but the complexity of EPA may make the preferred expression system a mammalian one. This is easily accomplished by transformation or by microinjection of eucaryotic (usually mammalian or vertebrate) cells with a suitable EPA vector. Eucaryotic transformation is in general a well-known process, and may be accomplished by a variety of standard methods. These include the use of protoplast fusion, chromosome transfection, lytic and nonlytic viral vectors (For example, Mulligan et al. , “Nature” (London) 277 : 108-114 [1979] , cell-cell fusion (Fournier et al. , "Proc. Nat. Acad. Sci.
  • Transformation which is mediated by lytic viral vectors is efficient but is disadvantageous for a number of reasons : the maximum size of transfected DNA is limited by the geometry of viral capsid packing, the exogenous genes are frequently deleted during viral replication, there is a requirement for helper virus or specialized hosts, host cells must be permissive, and the hosts are killed in the course of the viral infection.
  • Nonlytic transformations are based on the transcription and translation of virus vectors which have been incorporated into a cell line as a stable episome. These systems generally require unique cell lines and suffer from a number of disadvantages. See “Trends in Biochemical Sciences", June 1983, pp. 209-212.
  • Selection genes fall into three categories: Detectably amplified selection genes, dominant selection genes, and detectably amplified dominant selection genes. Detectably amplified selection genes are those in which amplification can be detected by exposing host cells to changes in the selection agent. Detectably amplified genes which are not dominant acting generally require a parental cell line which is genotypically deficient in the selection gene. Examples include the genes for hydroxymetholglutanyl CoA reductase (Sinensky, "Biochero. Biophys. Res. Commun” 78: 863 [1977], ribonucleotide reductase (Meuth et al.
  • DHFR dihydrofolate reductase
  • TK mouse thymidine kinase
  • Dominant selection genes are those which are expressed in transformants regardless of the genotype of the parental cell. Most dominant selection genes are not detectably amplified because the phenotype is so highly effective in dealing with the selection agent that it is difficult to discriminate among cell lines that have or have not amplified the gene. Examples of dominant selection genes of this type include the genes for procaryotic enzymes such as xanthine-guanine phosphoribosyltransferase (Mulligan et al. "Proc. Nat. Acad. Sci.” 78 [4] :2072-2076 [1981] and aminoglycoside 3' - phosphotransferase (Colbere-Garapin et al., "J. Mol. Biol.”, 150:1-14 [1981].
  • procaryotic enzymes such as xanthine-guanine phosphoribosyltransferase (Mulligan et al. "Proc. Nat. Acad. Sci.” 78 [4
  • Some dominant selection genes also are detectably amplified. Suitable examples include the mutant DHFR gene described by Haber et al., "Somatic Cell Genet.” 4:499-508 (1982), cell surface markers such as HLA antigens and genes coding for enzymes such as specific esterases that produce fluorescent or colored products from fluorogenic or chromogenic substrates as is known in the art.
  • Detectably-amplified, dominant selection genes are preferred for use herein. It should be understood that a dominant selection gene in some cases can be converted to a detectably amplified gene by suitable mutations in the gene.
  • vectors used in EPA transformation can contain a selection gene and the EPA gene.
  • other elements such as enhancers, promoters, introns, accessory DNA, polyadenylation sites and 3' noncoding regions as will be described below.
  • Suitable selection genes are described above. It is preferred that the selection agent be one that prevents cell growth in the absence of the selection gene. That way, revertant cells in large scale culture that lose the selection gene (and presumably the EPA gene as well) will not over-grow the fermentation.
  • a desirable selection gene would be one that enables transformants to use a nutrient critical for growth that they otherwise would not be able to use.
  • the TK gene described above is an example.
  • the first class are the unlinked vectors. Here the selection gene and the EPA gene are not covalently bound. This vector class is sometimes preferred because the step of ligating or otherwise bonding the two genes is not required. This simplifies the transformation process because the selection and product genes usually are obtained from separate sources and are not ligated in their wild-type environment. In addition, the molar ratio of the EPA and selection genes employed during transformation can be adjusted to increase transformation efficiency.
  • the second class of vectors is linked vectors. These vectors are distinguished from unlinked vectors in that the selection and EPA genes are covalently bound, preferably by ligation.
  • the vectors herein may also include enhancers. Enhancers are functionally distinct from promoters, but appear to operate in concert with promoters. Their function on the cellular level is not well understood, but their unique characteristic is the ability to activate or potentiate transcription without being position or orientation dependent. Promoters need to be upstream of the gene, while enhancers may be present upstream or 5' from the promoter, within the gene as an intron, or downstream from the gene between the gene and a polyadenylation site or 3' from the polyadenylation site. inverted promoters are not functional, but inverted enhancers are. Enhancers are cis-acting, i.e., they have an effect on promoters only if they are present on the same
  • Preferred enhancers are obtained from animal viruses such as simian virus 40 , polyoma virus , bovine papilloma virus, retrovirus or adenovirus.
  • the enhancer should be f rom a virus for which the host cell is permissive, i. e. which normally infects cells of the host type.
  • Viral enhancers may be obtained readily from publically available viruses.
  • the enhancer may be synthesized from sequence data; the sizes of viral enhancers (generally less than about 150 bp) are sufficiently small that this could be accomplished practically.
  • polyadenylation splicing site Another element which should be present in the vector assembly is a polyadenylation splicing (or addition) site. This is a DNA sequence located downstream from the translated regions of a gene, shortly downstream from which in turn transcription stops and adenine ribonucleotides are added, to form a polyadenine nucleotide tail at the 3' end of the messenger RNA. Polyadenylation is important in stabilizing the messenger RNA against degradation in the cell, an event that reduces the level of messenger RNA and hence the level of product protein.
  • Eucaryotic polyadenylation sites are well known. A concensus sequence exists among eucaryotic genes: The hexanucleotide 5'-AAUAAA-3' is found 11-30 nucleotides from the point at which polyadenylation starts. DNA sequences containing polyadenylation sites may be obtained from viruses in accord with published reports. Exemplary polyadenylation sequences can be obtained from mouse beta-globin, and simian virus 40 late or early region genes, but viral polyadenylation sites are preferred. Since these sequences are known, they may be synthesized in vitro and ligated to the vectors in conventional fashion.
  • a polyadenylation region must be located downstream from the EPA gene.
  • the sequence which separates the polyadenylation site from the translational stop codon is preferably an untranslated sequence
  • DNA oligonucleotide such as an unpromoted eucaryotic gene. Since such oligonucleotides and genes are not endowed with a promoter they will not be expressed.
  • the oligonucleotide should extend for a considerable distance, on the order of up to about 1,000 bases, from the stop codon to the polyadenylation site. This 3' untranslated oligonucleotide generally results in an increase in product yields.
  • the vector may terminate from about 10 to about
  • sequences typically extend about from 200 to 600 base pairs downstream from the polyadenylation site.
  • the vectors described herein may be synthesized by techniques well known to those skilled in this art.
  • the components of the vectors such selection genes, enhancers, promoters, and the like may be obtained from natural sources or synthesized as described above. Basically, if the components are found in DNA available in large quantity, e.g. components such as viral functions, or if they may be synthesized, e.g. polyadenylation sites, then with appropriate use of restriction enzymes large quantities of vector may be obtained by simply culturing the source organism, digesting its DNA with an appropriate endonuclease, separating the DNA fragments, identifying the DNA containing the element of interest and recovering same.
  • a transformation vector will be assembled in small quantity and then ligated to a suitable autonomously replicating synthesis vector such as a procaryotic plasmid or phage.
  • a suitable autonomously replicating synthesis vector such as a procaryotic plasmid or phage.
  • the pBR322 plasmid may be used in most cases.
  • the synthesis vectors are used to clone the ligated transformation vectors in conventional fashion, e.g. by transfection of a permissive procaryotic organism, replication of the synthesis vector to high copy number and recovery of the synthesis vector by cell lysis and separation of the synthesis vector from cell debris.
  • the resulting harvest of synthesis vector may be directly transfected into eucaryotic cells, or the transformation vector may be rescued from the synthesis vector by appropriate endonuclease digestion, separation by molecular weight and recovery of the transformation vector. Transformation vector rescue is not necessary so long as the remainder of the synthesis vector does not adversely affect eucaryotic gene amplification, transcription or translation.
  • the preferred synthesis vector herein is a mutant of the E. coli plasmid pBR322 in which sequences have been deleted that are deleterious to eucaryotic cells. See Kaufman et al., op. cit. Use of this mutant obviates any need to delete the plasmid residue prior to transformation.
  • the cells to be transformed can be any prokaryotic cell or any eucaryotic cell, including yeast protoplasts and insect cells, but ordinarily will be a nonfungal cell.
  • Candidate cells need not be genotypically deficient in the selection gene so long as the selection gene is dominant acting.
  • Eucaryotic cells preferably will be stable mammalian cell lines as is discussed above.
  • Cell lines that are known to stably integrate selection genes into their chromosomal DNA are best, for example Chinese hamster ovary (CHO) cell lines.
  • CHO Chinese hamster ovary
  • HeLa, COS monkey cells, melanoma cell lines such as the Bowes cell line, mouse L cells, mouse fibroblasts and mouse NIH 3T3 cells.
  • Microinjection of the vector into the cell nucleus will yield the highest DNA uptake efficiencies, but exposing parental cells to DNA in the form of a calcium phosphate precipitate is generally most convenient.
  • the population of cells that has been exposed to transforming conditions is then processed to identify the transformants. Only a small subpopulation of any culture which has been treated for transformation will exhibit the phenotype of the selection gene.
  • the cells in the culture are screened for the phenotype. This can be accomplished by assaying the cells individually with a cell sorting device where the phenotype is one that will produce a signal, e.g. fluorescence upon cleavage of a fluorogenic substrate by an enzyme produced by the selection gene.
  • the phenotype enables only transformants to grow or survive in specialized growth media as is further discussed above.
  • Selection transformants then will be screened for ligation of the product gene into their chromosomes or for expression of the product itself.
  • the former can be accomplished using Southern blot analysis, the latter by standard immunological or enzymatic assays.
  • steps are taken to amplify expression of the product gene by further cloning in the presence of a selection agent such as methotrexate (MTX).
  • MTX methotrexate
  • DNA sequence coding for a protein exhibiting EPA activity in accord with the present invention can be modified by conventional techniques to produce variations in the final EPA protein which still have EPA activity in the assay tests described herein.
  • one, two, three, four or five amino acids can be replaced by other amino acids.
  • EPA/cDNA in accord with this invention includes the mature EPA/cDNA gene preceded by an ATG codon and EPA/cDNA coding for allelic variations of EPA protein.
  • One allele is illustrated in Fig. 4.
  • the EPA protein of this invention includes the 1-methionine derivative of EPA protein (Met-EPA) and allelic variations of EPA protein.
  • the mature EPA protein illustrated by the sequence in Fig. 4 begins with the sequence Ala.Pro. Phe.Glu... the beginning of which is depicted by a arrow after nucleotide number 44 in Fig. 4.
  • the Met-EPA would begin with the sequence Met.Ala.Pro.Phe.Glu...
  • EPA protein of the present invention exhibits a specific activity of at least 10 6 units/mg of protein.
  • the EPA protein in accord with the present invention can be used for treatment of patients having low red blood cell counts to stimulate growth and formation of erythroid cells.
  • a daily dosage of about 200 to 1000 ug per patient is typically indicated.
  • the EPA protein is preferably injected into the patient intravenously in a suitable pharmacological carrier.
  • suitable pharmacological carrier include pharmacological saline and human serum albumin in saline.
  • embodiments of the invention and subject matter provided thereby include, without limitation: 1) a method for preparing an expression vector containing an EPA gene or DNA sequence coding for EPA, said method being as generally outlined and specifically described herein; 2) cells transformed with an expression vector prepared according to the method indicated in 1), above, including 2-A) prokaryotic cells, 2-B) eukaryotic cells and 2-C) mammalian cells; 3) cloned DNA sequences which code for EPA including the sequences 3-A) set forth in Fig. 4 and 3-B) set forth in Fig.
  • EPA protein having the amino acid sequence set forth in Fig. 5 or an allelic variation thereof; 12) cDNA which codes for EPA including 12-A) cDNA having the nucleotide sequence illustrated in Fig. 4 and 12-B) cDNA having the nucleotide sequence illustrated in Fig. 5; 13) expression vectors comprising cDNA coding for EPA including 13-A) those comprising the nucleotide sequence illustrated in Fig. 4 and 13-B) those comprising the nucleotide sequence illustrated in Fig.
  • 14 cells transformed with an expression vector as indicated in 13, 13-A and 13-B, above, including in each case 14-A) prokaryotic cells, 14-B) eukaryotic cells, 14-C) yeast cells, 14-D) mammalian cells and 14-E) insect cells; 15) EPA protein made by expressing cDNA coding for EPA in a transformed cell including 15-A) prokaryotic cells, 15-B) eukaryotic cells, 15-C) yeast cells, 15-D) mammalian cells and 15-E) insect cells; 16) EPA protein substantially free of other protein of native origin; 17) EPA protein glycosylated by expression of cDNA coding for EPA in a transformed eukaryotic cell including 17-A) mammalian cell and 17-B) insect cells; 18) EPA protein made by expressing in a cell cDNA having the nucleotide sequence illustrated in Fig.
  • restriction endonucleases are utilized under the conditions and in the manner recommended by their commercial suppliers. Ligation reactions are carried on as described by Maniatis, T. et al.. Molecular Cloning - A Laboratory Manual Cold Spring Harbor Laboratory, Cold Spring Harbor, NY 1982 p. 245-6, the disclosure of which is incorporated herein by reference, using the buffer described at page 246 thereof and using a DNA concentration of 1-100 ug/ml, at a temperature of 23°C for blunt ended DNA and 16°C for "sticky ended" DNA. "Phosphatasing" as described herein, refers to dephosphorylation of DNA, and is carried out in the manner described by Maniatis et al., supra, e.g.
  • Binasing refers to phosphorylation of DNA. Electrophoresis is done in 0.5-1.5% Agarose gels containing 90 mM Tris-borate, 10 mM EDTA. "Nick-translating” refers to the method for labeling DNA with 32p as described by Rigby et al., J. Mol. Biol., 113:237 (1977). All radiolabeled DNA is labeled with 32p, whatever labelling technique was used.
  • rapid prep is meant a rapid, small scale production of bacteriophage or plasmic DNA, e.g., as described by Maniatis et al., supra, at p. 365-373.
  • temperatures are in °C.
  • Iscove' s modified Dulbecco' s medium containing antibiotics were incubated for an additional week, and then removed by centrif ugation. After collection the medium was heated to 56°C for 30 min to inactivate the HTLV-II.
  • step B Biological Assays For EPA Activity
  • fetal bovine serum (Irvine Scientific and Hy clone selected lots) , 0.5 U/ml of human urinary erythropoietin (supplied by the National Heart, Lung and Blood Institute about 1 ,140 U/mg protein) , 10 -6 M FeCl 3 , 4.4 uM human transferrin, 1000 U/ml penicillin and 1000 ug/ml streptomycin, 10 -4 M alpha-thioglycerol, 10 - 7 M selenium, 0.035 percent dextrose and Iscove' s medium.
  • the assays were done in 96-well tissue culture plates (Costar) ; each well contained 0.1 ml of methylcellulose mixture with cells at a density of 4 to 5 x 10 5 per ml, and 0.01 ml of test material.
  • the material to be tested was dissolved in Dulbecco' s phosphate-buffered saline (PBS; Irvine Scientific) containing 0.01 percent bovine serum albumin and sterile f iltered. Two-fold serial dilutions were made; each dilution was assayed in duplicate. Erythroid bursts were scored at 7 to 10 days using an inverted microscope. These bursts contain a minimum of 50 cells and are reddish brown in color indicating hemoglobinization of cells. Typically, control wells contained approximately 30 erythroid bursts per well. The last dilution which gave stimulation greater than 30 percent above control was considered to have 1 unit/ml of EPA.
  • BFU-E were also assayed f rom normal human bone marrow by a modif ication of a previously described technique, which employs microtiter dishes (Hunt, et al , supra) ; light density bone marrow cells were plated at 3 x 10 5 cells/ml in Iscove' s medium containing 10 percent fetal bovine serum, 1 U/ml of human erythropoietin, 0.8 percent methylcellulose. and antibiotics.
  • step c Purification Of EPA
  • Phenylmethylsulfonyl fluoride was added to 10 liters of conditioned medium at a final concentration of 1 mM to inhibit proteolysis.
  • the medium was then concentrated 15-fold with an Amicon hollow-fiber apparatus , using a Type H1P10-8 filter.
  • the concentrate was brought to 80 percent saturation by the addition of sol id ammonium sulfate.
  • the precipitate was collected after stirring on ice for 4 to 12 hours, dialyzed against PBS, and clarif ied by centrif ugation. This material was applied to a column (2.6 cm x 6 cm) of lentil lectin Sepharose 4B (Pharmacia) that had been equilibrated with PBS.
  • the column was then washed with two column volumes of buffer, and EPA was eluted with 15 ml of 0.5 M alpha-methyl-D-mannoside in PBS.
  • the eluate was collected and concentrated in an amicon stirred ultraf iltration cell, using a PM10 membrane, to a volume of 6 ml.
  • the material was then applied to an Ultrogel ACA 44 column (1.6 x 80 cm; LKB) equilibrated with PBS as the running buffer. The flow rate was 6 ml per hour, and fractions of 2.5 ml were collected. Fractions with the highest specific activity were combined and applied directly to the HPLC column without additional manipulation.
  • Reverse phase high performance liquid chromatography HPLC was performed on a Beckman apparatus , using a Vydac C-18 (10 x 250 mm) column with a starting solvent of 10 percent acetonitrile and 0.1 percent trifluoroacetic acid in water.
  • the column was eluted with increasing concentrations of acetonitrile in trifluoroacetic acid using the following gradient : 10 percent to 30 percent acetonitrile over 10 rain, then 30 percent to 60 percent over 60 rain.
  • the flow rate was 1.5 ml per min.
  • Ultraviolet absorbance was monitored at 220 nm, and protein peaks were collected manually, evaporated to dryness, and resuspended in a small volume of PBS.
  • Sodium dodecyl sulfate polyacrylamide gel electrophoresis was performed according to the method described by Laemmli, Nature 227, pp. 680-5 (1970). Proteins were visualized by iodination prior to electrophoresis. Iodinations were performed using a modification of the chloramine T method described by Hunter, et al, Nature 194. pp. 495-6 (1962); after reaction with 125 I and chloramine T the samples were not desalted by gel filtration but were applied directly to the gel. The tracking dye was electrophoresed to the end of the gel and excess 125 I migrated as the dye front. This procedure obviated the need for the addition of carrier protein and allowed complete recovery of small amounts of protein. The gels were fixed in 50 percent methanol, 10 percent acetic acid, soaked in 2 percent glycerol, dried, and exposed to film for 1 to 12 hours.
  • EPA from the earlier purification steps (ammonium sulfate precipitation and lentil lectin eluate) was inhibitory at moderate concentrations. Because of these considerations it was necessary to assay EPA over a wide concentration range for accurate quantitation. The addition of 0.01 percent bovine serum albumin to the dilutions was necessary to prevent loss by nonspecific adsorption, especially during sterile filtration. Bovine serum albumin has a slight stimulatory effect in the assay; however, this effect was negligible at the concentration (0.01 percent) used.
  • the first probe consisted of all sixty-four possible 12-mers that encode residues 9-13 of the above sequence (i.e. Q T A F). These oligonucleotides were synthesized in 8 pools each containing 8 sequences that would be complementary to the EPA mRNA sequence as follows:
  • the second probe consisted of all sixty-four 14-mers predicted f rom the sequence of residues 21-25 (AKFVG) . Again, these compounds were synthesized in 8 pools of 8 sequences complementary to the mRNA sequence :
  • 53-mers covered the region f rom residue 9 to residue 26 .
  • One pool (53-1) was synthesized to be complementary to the mRNA, while the other ( 53-2) was synthesized to have the same sense as the mRNA.
  • the sequences were as follows :
  • Mo cells were induced for 24 hr with PHA and PMA to enhance their lymphokine production (2 x 10 9 cells at 10 6 cells/ml in RPMI 1640 + 5% FCS). The cells were collected by centrifugation and cytoplasmic RNA was prepared by a standard gentle lysis procedure. Polyadenylated messenger RNA was prepared by chromatography on oligo dT cellulose.
  • First strand cDNA was prepared using standard methods beginning with lOug of mRNA. The mRNA was removed by base treatment and the cDNA was purif ied by gel exclusion chromatography (Sepharose CL-4B) and concentrated by ethanol precipitation. The yield was approximately 1 ug.
  • the 1st strand cDNA was hybridized in 10ul with an excess of mRNA isolated f rom cells which do not make lymphokines.
  • the cell lines used were Daudi (a B-cell l ine) and CEM (an immature T-cell line) .
  • Most of the sequences expressed in Mo, CEM and Daudi will be the same and only a small fraction will be found only in Mo. Therefore, by hybridizing 10 ug of CEM mRNA and 10 ug of Daudi mRNA to 1 ug of Mo cDNA we expected that most of the cDNA would anneal to its complementary mRNA and become double- stranded.
  • the Mo lymphokine cDNAs should remain single-standed. Since double and single stranded molecules can be resolved by chromatography on hydro-cylapatite, a substantial enrichment for lymphokine sequences should be achieved. After 18-24 hrs at 65° , the RNA:cDNA hybridization was passed over a 1 ml hydroxylapatite column. The flow through of the column was collected (the single-strand f raction) and used to make a cDNA library. Roughly 5% of the input cDNA was recovered. More than 90% was retained on the column (double-stranded) suggested that a 10-20 fold enrichment had been achieved.
  • the single-stranded cDNA was concentrated by butanol extraction, passed over Sepharose Cl-4B to remove phosphate buffer and collected by ethanol precipitation.
  • the cDNA was then converted to a double-stranded form by treatment with the Klenow fragment of DNA polymer ase I using standard methods.
  • the "loopback" form was cleaved with Sl-nuclease and "C-tails" added with terminal transf erase by standard methods.
  • the tailed cDNA was annealed with G-tailed pBR322 (at the Pstl site) and used to transform E. coli.
  • the plasmid DNA in each colony was amplified in situ by tansf erring the f ilters to fresh plates and incubating overnight at 37° . Finally, these repl ica f ilters were prepared for standard colony hybridization by treatment with base followed by neutralization and drying. The dried f ilters were baked in vacuo for 2 hours at 80° to fix the liberated DNA to the nitrocellulose.
  • step F Colony Hybridization
  • Step G Southern Analysis Of The Potential EPA Clones
  • Step H Sequencing The Candidate EPA Clones
  • the purified protein we first determined which of the 8 pools of eight 14-mers best hybridized to the clone. To do this each pool was labelled separately with poly nucleotide kinase and 32 P-ATP and hybridized separately to a replica Southern f ilter prepared as described above, pool 14-5 proved to hybridize most strongly to clones 27, 57 and 58, indicating that this pool of oligonucleotides would be a good primer for dideoxy sequencing of the candidate clones.
  • CsCl purified clone 58 DNA was denatured with base and sequenced using standard dideoxy sequencing with pool 14-5 as primer. This primer gave an unambiguous DNA sequence which clearly encoded residues 19 back to 1.
  • clone 58 contained 17 codons from a potential signal peptide. From this result, we concluded that we had identified a clone encoding the purified EPA protein. Since we were confident that clones 27 and 57 also encoded the EPA polypeptide, we determined the complete nucleotide sequence of all three clones.
  • step l Expression Of EPA In Mammalian cells
  • the Bgl I cut DNA was treated with the nuclease Bal 31 for a time sufficient to remove approximately 150 base pairs per end or 300 total from the DNA.
  • the DNA was then cleaved with Pvul which cuts pBR322 126 nucleotides on the other side of the Pstl site from the Bgl I site.
  • This DNA was treated with the Klenow fragment of DNA polymerase I to render the ends blunt then ligated overnight with synthetic EcoRl linkers.
  • the excess polymerized linkers were removed by digestion with EcoRl and the approximately 800 base pair fragment was isolated from a preparative agarose gel. This DNA was recovered by the standard glass powder isolation method and was ligated to EcoRl linearized
  • Colonies containing EPA inserts were identified by colony hybridization using the labelled 14-mer (pool 14-5) as probe. Twelve colonies that scored as positive were picked, and their DNAs were prepared and analyzed by digestion with EcoRl.
  • E. coli and clones carrying the desired insert were identified by colony hybridization again, using labeled pool 14-5 DNA as probe.
  • the vector pAdD26SVpA(3) was described by (Kaufman et al. , Mol . Cell Biol. 2(11) : 1304-1319 [1982] . It has the structure illustrated in Fig. 1. Briefly this plasmid contains a mouse dihydrofolate reductase (DHFR) cDNA gene that is under transcriptional control of the adenovirus 2 (Ad2) major late promoter. A 5 ' splice site is included in the adenovirus DNA and a 3 ' splice site, derived f rom an immunoglobulin gene, is present between the Ad2 maj or late promoter and the DHFR coding sequence.
  • DHFR mouse dihydrofolate reductase
  • the SV40 early polyadenylation site is present downstream from the DHFR coding sequence.
  • the procaryotic-derived section of pAdD26SVpA(3) is from pSVOd (Mellon, P. , Parker, V. , Gluzman, Y. and Maniatis, T. 1981 , Cell 27: 279-288) and does not contain the pBR322 sequences known to inhibit replication in mammalian cells (Lusky, M. , and Bot chan, M. 1981 , Nature (London) 293: 79-81.
  • pAdD26SVpA(3) was converted into plasmid pCVSVL2 as illustrated in Fig. 1.
  • pAdD26SVpA(3) was converted into plasmid pAdD26SVpA(3) (d) by deletion of one of the two Pstl sites in pAdD26SVpA(3) .
  • VA genes were inserted into pAdD26SVpA(3) (d) as illustrated in
  • pAdD26SVpA(3) (d) was cleaved with PvuII to make a linear molecule opened within the 3' portion of the first of the three elements comprising the tripartite leader. Then, pJAW 43
  • the ligation product was used to transform E. coli to tetracycline resistance and colonies were screened using the
  • the Ava II D fragment of SV40 containing the SV40 enhancer sequence was obtained by digesting SV40 DNA with Ava II, blunting the ends with Klenow fragment of Pol I, ligating Xho I linkers to the fragments, digesting with Xho I to open the Xho I site, and isolating the fourth largest (D) fragment by gel electrophoresis.
  • Fragment in pCVSVL2-TPL was such that the SV40 late promoter was in the same orientation as the adenovirus major late promoter.
  • adenovirus virus associated (VA) genes into the pCVSVL2-TPL
  • a plasmid was constructed that contained the adenovirus type 2 Hind III B fragment.
  • Adenovirus type 2 DNA was digested with Hind III and the B fragment was isolated after gel electrophoresis. This fragment was then inserted into pBR32 which had previously been digested with Hind III. After transformation of E. coli to ampicillin resistance, the recombinants were screened for insertion of the Hind III B fragment and the inserted orientation was determined by restriction enzyme digestion.
  • pBR322 - Ad Hind III B contains the adenovirus type 2 Hind Ill B fragment in the orientation depicted in Fig. 2.
  • the VA genes were conveniently obtained from plasmid pBR322-Ad Hind II by digesting with Hpa I, ligating EcoRl linkers and digesting with EcoRl, and recovering the 1.4kb fragment. This fragment having EcoRl sticky ends was then ligated into the EcoRl site of pCVSVL2-TPL (which had previously been digested with EcoRl). After transformation of E. coli HB101 and selection for tetracycline resistance, colonies were screened by filter hybridization to a DNA probe specific to the VA genes. DNA was prepared from positively hybridizing clones and characterized by restriction endonuclease digestion. The product plasmid was designated p91023. The 2 EcoRl sites in p91023 were removed. p91023 was cut to completion with EcoRl, generating two DNA fragments: one, about
  • both fragments are filled in using the Klenow fragment of Poll, and then both fragments, i.e. 1.3 Kb and 7Kb, were religated together.
  • a plasmid p91023(A) containing the VA genes and similar to p91023 but deleted for the 2 EcoRl sites was identified by Grunstein-Hogness screening with the VA gene fragment, and by conventional restriction site analysis.
  • p91023(A) was removed and replaced with an EcoRl site (Fig. 3).
  • p91023(A) was cut to completion with Pstl, and then treated with Klenow fragment of Poll to generate flush ends.
  • EcoRl linkers were ligated to the blunted Pstl site of p91023(A).
  • the linear p91023(A), with EcoRl linkers attached at the blunted Pstl site, was separated from unligated linkers and digested to completion with EcoRl, and then religated.
  • a plasmid p91023(B) was recovered and identified to have a structure similar to p91023(A), but with an EcoRl site situated at the previous Pstl site.
  • EPA clone 57 prepared as described above was digested with EcoRl to obtain the DNA coding for EPA. This DNA was ligated into the EcoRl site of p91023(B). Monkey COS-7 cells were transfected with the EPA containing plasmids and grown to express EPA.
  • DNA transfections were performed as described by sompayrac & Danna, Proc. Natl. Acad. sci.. 78. pp. 7575-8 (1981), with the addition of chloroquin treatment (Luthman and Magnusson, Nuc. Acids Res. 11, pp. 1295-1308 (1983) ) .
  • Cells were rinsed with serum free media, and incubated at 37 degrees for 12 hours in Dulbecco' s modif ied Eagle' s medium containing DEAE Dextran (MW 5 ,000 ,000 Pharmacia, 250 mg/ml) with .
  • IM Tris pH 7.3 and 2 ug/ml of plasmid DNA After incubation, the cells were rinsed with serum free media and treated 2 hours at 37 degrees with 1mM chlorquin in media containing serum. Cells were subsequently fed with media and incubated for indicated periods of time.
  • step K Expression Of EPA In E. Coli
  • the pALP-181 vector fragment was prepared by Kpnl digestion which opens the plasmid immediately adjacent to the ATG to be used in expressing proteins. By treating with Klenow, the Kpnl sticky ends are removed leaving a flush ATG in the desired location. Cleavage of the vector with BamHl renders the vector capable of ligating with the flush to BamHl fragment carrying the mature coding region of EPA. These two DNAs were ligated together and used to transform E.
  • coli W3110 lambda Y139 a strain carrying a temperature sensitive lambda repressor protein (plating is done at 30° to keep the P L promoter of pALP-181 turned off). Colonies from the transformation were lifted onto filters and two replica filters were prepared for colony hybridization. One replica was hybridized to the primer repair oligonucleotide and the second filter was hybridized to a junction oligonucleotide having the sequence d(T-A-C-A-T-A-T-G-T-G-C-A-C-C-T) which spans the desired correct sequence of the mature EPA sequence fused to the ATG of the expression plasmid.
  • step A mRNA Preparation From The Gibbon T-Cells
  • UCD-MLA 144 A sample of the gibbon T-cell line designated UCD-MLA 144 was cultured for several weeks in RPMI 1640. (purchased from Gibco) and 20% fetal calf serum (FCS) until there was obtained 1 x 10 9 total cells. The cells were induced to produce high levels of EPA by activation for 24 hours in the presence of 10 nanograms per ml 12-0-tetradecanoylphorbol-
  • TPA 13-acetate
  • MBP Membrane bound polysome
  • step B First strand CDNA Reaction
  • MBP mRNA 6 ug of MBP mRNA (from Step A) was diluted into a 50 ul cDNA synthesis reaction mixture in accord with standard methods (Maniatis et al., supra) and the reaction initiated by the addition of reverse transcriptase. After incubation for 30 minutes at 42°C, the reaction was stopped by addition of EDTA to 50 mM, and diluted with H 2 O to 100 ul. The mixture was extracted with phenol/chloroform and further extracted with chloroform. The cDNA/RNA hybrids were separated from unincorporated triphosphates by chromatography on a 2 ml Sepharose CL-4B column. The excluded fractions were pooled and the hybrids collected by ethanol precipitation. The final yield was 570 ng.
  • the first strand cDNA pellet (from Step B) was resuspended in 50 ml of H 2 O, and second strand synthesis carried out in a standard reaction mixture with E. coli Polyraerase I, E. coli ligase, and RNAse H. The reaction was incubated overnight at 16°C and then incubated for 1 hour at 37°C. The reaction was stopped by addition of EDTA and extracted with phenol/chloroform. The cDNA was separated from unincorporated triphosphates by chromatography on a Sepharose CL-4B column, the excluded fractions pooled and the cDNA collected by ethanol precipitation.
  • step D Recombinant cDNA Preparation
  • the cDNA pellet (from Step C) was resuspended in 75 ul of H 2 O. Homopolymeric C "tails" were added to the ends of the cDNA by adding 10 ul of the cDNA solution to a 25 ul standard reaction mixture with terminal transferase, and incubating at 30°C for 5 minutes. The reaction was stopped by the addition of EDTA to 40 mM and and heat inactivation at 68°C for 10 minutes. 10 ng of this tailed cDNA was annealed with 50 ng of G-tailed ⁇ BR322
  • step E Bacterial Transformation
  • E. coli strain MC1061 was grown in L-broth, chilled on ice, harvested by centrifugation, and treated wth CaCl 2 to prepare them for transformation. 5 ul of the cDNA annealing reaction was then incubated with 200 ul of the CaCl 2 -treated bacteria. 15 such transformations were performed, using all of the annealed cDNA, and spread on 15 cm 1% agar L-broth plates containing 10 ug/ml tetracycline. Approximately 1000 colonies grew on each plate.
  • step F Replica Plating
  • the cDNA insert from EPA Clone 57 was isolated by digestion with the restriction enzyme EcoRl, and electrophoresis in an agarose gel with Tris acetate and ethidium bromide. The band containing the cDNA fragment was cut from the gel and purified by the glass powder technique.
  • T4 DNA Polymerase Buffer (0.33 M Tris Acetate, pH 7.9, 0.66 M potassium acetate, 0.1 M Magnesium acetate and 10 mM dithiothreitol), and 3 units of T4 DNA Polymerase (New England Biolabs), and diluted with water to 10 ul.
  • the unincorporated triphosphates were separated from the labelled cDNA by chromatography on a Sephadex G100 column.
  • a second probe was prepared from a synthetic oligonucleotide having the sequence:
  • ATG GCC CCC TTT G which is complimentary to the amino terminus of the EPA coding region.
  • This oligonucleotide was labelled with 32 P dATP at its end using a standard polynucleotide kinase reaction.
  • Step H Isolation of Gibbon EPA cDNA Clones

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Une protéine présentant une activité d'activation d'érythroïdes (EPA) a une activité biologique d'au moins 106 unités par mg environ de protéine et un poids moléculaire apparent de 28.000 daltons environ déterminé par une analyse de SDS-PAGE sur 10% de polyacrylamide colloïdale. Un gène cloné d'EPA code cette protéine EPA, un vecteur recombinant contient ce gène d'EPA, un microorganisme ou cellule d'un mammifère est transformé par ce vecteur recombinant, et un procédé permet de produire de l'EPA en exprimant le gène d'EPA dans une culture dudit microorganisme ou de ladite cellule de mammifère. L'EPA purifié stimule la croissance de précurseurs d'érythroïdes primaires ou secondaires à partir de la moëlle osseuse humaine, ainsi que la formation en colonie par la lignée cellulaire K562 d'érythroleucémie.
PCT/US1985/001900 1984-10-01 1985-10-01 Vecteurs contenant un gene pour une proteine presentant une activite d'activation d'erythroides et procede par adn recombinant de production de cette proteine WO1986002100A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US65659084A 1984-10-01 1984-10-01
US656,590 1984-10-01

Publications (1)

Publication Number Publication Date
WO1986002100A1 true WO1986002100A1 (fr) 1986-04-10

Family

ID=24633705

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1985/001900 WO1986002100A1 (fr) 1984-10-01 1985-10-01 Vecteurs contenant un gene pour une proteine presentant une activite d'activation d'erythroides et procede par adn recombinant de production de cette proteine

Country Status (3)

Country Link
EP (1) EP0198014A4 (fr)
JP (1) JPS62500424A (fr)
WO (1) WO1986002100A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188312A2 (fr) * 1985-01-07 1986-07-23 Celltech Limited Procédé de production d'une protéine
EP0211077A1 (fr) * 1985-02-05 1987-02-25 Synergen Biolog Inc Vecteurs recombinants de sequences d'inhibiteurs de metalloproteinase, systeme d'utilisation et procede de production de ces vecteurs grace a l'adn recombinant.
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU589935B2 (en) * 1985-01-07 1989-10-26 Celltech Limited Recombinant DNA processes for the production of tissue inhibitor of metalloproteinase
DE3666826D1 (en) * 1985-01-18 1989-12-14 Searle & Co Human natural inhibitor of collagenases
AU5549386A (en) * 1985-02-05 1986-08-26 Synergen Biologicals Inc. Metalloproteinase inhibitor sequence recombinant vector system for using same and recombinant dna for the manufactureof same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KOEFFLER et al, Blood Vol. 64 pp 482-490 August 1984 *
See also references of EP0198014A4 *
TANIGUCHI et al, Nature Vol. 302 pp 305-310 24 March 1983 *

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0188312A2 (fr) * 1985-01-07 1986-07-23 Celltech Limited Procédé de production d'une protéine
EP0188312A3 (fr) * 1985-01-07 1988-01-13 Celltech Limited Procédé de production d'une protéine
EP0211077A1 (fr) * 1985-02-05 1987-02-25 Synergen Biolog Inc Vecteurs recombinants de sequences d'inhibiteurs de metalloproteinase, systeme d'utilisation et procede de production de ces vecteurs grace a l'adn recombinant.
EP0211077A4 (fr) * 1985-02-05 1987-11-23 Synergen Biolog Inc Vecteurs recombinants de sequences d'inhibiteurs de metalloproteinase, systeme d'utilisation et procede de production de ces vecteurs grace a l'adn recombinant.
US7247704B2 (en) 2000-12-18 2007-07-24 Arriva Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease
US7709446B2 (en) 2000-12-18 2010-05-04 Arrive Pharmaceuticals, Inc. Multifunctional protease inhibitors and their use in treatment of disease

Also Published As

Publication number Publication date
JPS62500424A (ja) 1987-02-26
EP0198014A4 (fr) 1987-11-23
EP0198014A1 (fr) 1986-10-22

Similar Documents

Publication Publication Date Title
EP0337359B1 (fr) Préparation et purification de lymphokines
EP0162067B1 (fr) Production du facteur viii et des produits relatifs
US5891429A (en) Recombinant human granulocyte-macrophage-colony stimulating factor (GM-CSF)
FI103986B (fi) cDNA-kloonit, jotka koodaavat polypeptidejä, joilla on humaani sellulaarinen granulosyyttimakrofaagi- ja eosinofiili-kasvutekijäaktiivisuus
EP0182448A2 (fr) Production de facteur VIII et produits apparentés
US5720952A (en) Method of treating myelo-suppression with GM-CSF
CA1335717C (fr) Facteur stimulant les colonies de granulocytes et de macrophages humains et ses muteines derivees
JPH0657152B2 (ja) Ｃｓｆ遺伝子類
WO1986002100A1 (fr) Vecteurs contenant un gene pour une proteine presentant une activite d'activation d'erythroides et procede par adn recombinant de production de cette proteine
KR920002312B1 (ko) 인체 과립성 백혈구의 콜로니 자극인자
Corbo et al. Expression of interleukins in L cells transfected with human DNA
HU204086B (en) Process for producing non-human mammal animal interferons, dna sequemces coding form them and pharmaceutical compositions comprising sand interferons

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE FR GB IT LU NL SE

WWE Wipo information: entry into national phase

Ref document number: 1985905157

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1985905157

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1985905157

Country of ref document: EP